Piper Sandler Maintains Akoya Biosciences(AKYA.US) With Buy Rating, Cuts Target Price to $4
Akoya Biosciences Analyst Ratings
Piper Sandler Maintains Overweight on Akoya Biosciences, Lowers Price Target to $4
Morgan Stanley Downgrades Akoya Biosciences(AKYA.US) to Hold Rating, Cuts Target Price to $3
Hold Rating on Akoya Biosciences Amidst Solid Operations and Market Headwinds
Craig-Hallum Maintains Akoya Biosciences(AKYA.US) With Buy Rating, Announces Target Price $7
A Quick Look at Today's Ratings for Akoya Biosciences(AKYA.US), With a Forecast Between $6 to $6
Akoya Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Alignment Healthcare (ALHC) and Akoya Biosciences (AKYA)
Akoya Biosciences (AKYA) Was Downgraded to a Hold Rating at BTIG
Craig-Hallum Releases a Buy Rating on Akoya Biosciences (AKYA)
Akoya Biosciences Analyst Ratings
Morgan Stanley Maintains Overweight on Akoya Biosciences, Lowers Price Target to $4
Buy Rating on Akoya Biosciences: Temporary Setbacks, Growth Potential, and an Attractive Entry Point
Analysts' Top Healthcare Picks: Akoya Biosciences (AKYA), Rubicon Organics (ROMJF)
Piper Sandler Cuts Akoya Biosciences Price Target to $6 From $8, Maintains Overweight Rating
Akoya Biosciences Analyst Ratings
BTIG: Maintains Akoya Biosciences (AKYA.US) rating, adjusted from buy to buy rating, and adjusted target price from $9.00 to $6.00.
Piper Sandler Reaffirms Their Buy Rating on Akoya Biosciences (AKYA)
Piper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)